Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements 2024
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show 2024
Spring on the Road
Spring Wellness 2025
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
Ontario Votes
Parcel Pick Up
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Insmed Incorporated - Common Stock
(NQ:
INSM
)
76.55
+1.48 (+1.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Insmed Incorporated - Common Stock
< Previous
1
2
3
4
5
Next >
Are Small-Cap Stocks A Buy After Russell 2000 Correction?
March 06, 2025
Investors are questioning the value of small-cap stocks, as reflected by Russell 2000's 15% drop. Some top stocks saw even bigger declines.
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
March 05, 2025
Via
Benzinga
First Trust's New Small-Cap ETF Aims To Combine Growth With Income
February 28, 2025
First Trust launches actively managed FTKI ETF, using buy-write strategy for steady income and small-cap exposure. Expense ratio is 0.85%.
Via
Benzinga
Topics
ETFs
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
February 25, 2025
RBC Capital initiates Insmed with an Outperform rating, citing brensocatib's launch potential and Arikayce's growth. FDA decision on brensocatib due August 2025.
Via
Benzinga
Exposures
Product Safety
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
February 25, 2025
Via
Benzinga
Earnings Scheduled For February 20, 2025
February 20, 2025
Via
Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
February 14, 2025
Via
Benzinga
Peering Into Insmed's Recent Short Interest
February 14, 2025
Via
Benzinga
Insmed Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
February 11, 2025
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
February 05, 2025
Via
Benzinga
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert
January 16, 2025
Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis.
Via
Stocktwits
Topics
Government
Exposures
Political
How Is The Market Feeling About Insmed?
January 13, 2025
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
January 10, 2025
The Benzinga Stock Whisper Index looks at five stocks receiving increased attention from readers during the week and provides potential reason why.
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
January 02, 2025
Via
Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today
December 16, 2024
Via
Benzinga
How Is The Market Feeling About Insmed?
December 03, 2024
Via
Benzinga
Demystifying Insmed: Insights From 7 Analyst Reviews
November 22, 2024
Via
Benzinga
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank
December 17, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst
November 20, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
November 19, 2024
Via
Benzinga
Insmed's Options: A Look at What the Big Money is Thinking
November 18, 2024
Via
Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
November 08, 2024
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the past week. Several of this week's stocks may have gotten a Trump bump.
Via
Benzinga
Topics
Government
Exposures
Political
A Glimpse of Insmed's Earnings Potential
October 30, 2024
Via
Benzinga
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
October 25, 2024
Via
Benzinga
Peering Into Insmed's Recent Short Interest
October 24, 2024
Via
Benzinga
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
October 15, 2024
Via
Benzinga
Here's How Much You Would Have Made Owning Insmed Stock In The Last 10 Years
September 20, 2024
Via
Benzinga
(INSM) - Analyzing Insmed's Short Interest
September 16, 2024
Via
Benzinga
Here's How Much $1000 Invested In Insmed 10 Years Ago Would Be Worth Today
September 10, 2024
Via
Benzinga
$1000 Invested In Insmed 10 Years Ago Would Be Worth This Much Today
August 26, 2024
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.